The US Food and Drug Administration is concerned that Spectrum Pharmaceuticals Inc. had not begun enrolling patients in a confirmatory trial of its targeted non-small cell lung cancer drug Pozenveo (poziotinib) as of the end of July.
The company is seeking accelerated approval of the drug. FDA said postmarketing studies should be underway at the time of submission of a marketing application for accelerated approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?